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Abstract
Although anoikis resistance has been considered a hallmark of malignant phenotype, the causal relation between
neoplastic transformation and anchorage-independent growth remains undefined. We developed an experimental
model of murine melanocyte malignant transformation, where a melanocyte lineage (melan-a) was submitted to
sequential cycles of anchorage blockade, resulting in progressive morphologic alterations, and malignant transfor-
mation. Throughout this process, cells corresponding to premalignant melanocytes and melanoma cell lines were
established and show progressive anoikis resistance and increased expression of Timp1. In melan-a melanocytes,
Timp1 expression is suppressed by DNA methylation as indicated by its reexpression after 5-aza-2′-deoxycytidine
treatment. Methylation-sensitive single-nucleotide primer extension analysis showed increased demethylation in
Timp1 in parallel with its expression alongmalignant transformation. Interestingly, TIMP1 expression has already been
relatedwith negative prognosis in some human cancers. Although described as aMMP inhibitor, this protein has been
associated with apoptosis resistance in different cell types. Melan-a cells overexpressing Timp1 showed increased
survival in suspension but were unable to form tumors in vivo, whereas Timp1-overexpressing melanoma cells
showed reduced latency time for tumor appearance and increased metastatic potential. Here, we demonstrated
for the first time an increment in Timp1 expression since the early phases of melanocyte malignant transformation,
associated to a progressive gene demethylation, which confers anoikis resistance. In this way, Timp1 might be con-
sidered as a valued marker for melanocyte malignant transformation.
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Introduction
Several studies have shown that cell interaction with extracellular
matrix (ECM) is crucial for survival, proliferation, migration, and
differentiation [1]. The physical link between them is mediated by
integrins, α/β heterodimeric transmembrane glycoproteins that con-
nect ECM proteins to actin cytoskeleton and play a critical role
transducing bidirectional signals between extracellular and intracel-
lular compartments [2]. Loss of integrin-matrix contacts results in a
type of apoptosis, termed anoikis, even in the presence of all required
growth factors and nutrients [3]. The acquired ability to survive inde-
pendently of anchorage is known as a hallmark of malignant transfor-
mation, by increasing the survival in absence of attachment and
facilitating migration and colonization at distant sites [4]. In animal
models, anoikis-resistant tumors present increased incidence of meta-
static lesions and number of circulating cells in blood [5,6]. Deletion
of tumor suppressor genes, overexpression of oncogenes, alterations in
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adhesion molecules pattern, enhancement in survival signals, as well
as inactivation of molecules involved in survival signaling render cells
resistant to anoikis, which may be influenced by environment, genetic,
and epigenetic factors, contributing to early steps of carcinogenesis
and also tumor progression [7]. Although anoikis resistance has been
described in many types of human malignancies, including mela-
noma [6], the causal relation between neoplastic transformation and
anchorage-independent growth remains undefined.
The tissue inhibitor of metalloproteinase (Timp) family consists of
four members (Timp1, 2, 3, and 4) that act as endogenous inhibitors
of matrix metalloproteinases (MMPs) [8]. The balance between MMPs
and Timps activities is involved both in normal and pathologic events
such as wound healing, tissue remodeling, angiogenesis, invasion, and
metastasis [9]. Almost all human cancers have been found to augment
expression and activity of MMPs. Interestingly, Timps are often found
upregulated in many tumors. TIMP1 expression has been related with
negative prognosis in many human cancers including metastatic breast
cancer, colorectal cancer, lymphoma, and non–small cell lung car-
cinoma, suggesting a promising value for TIMP1 as a prognostic
marker for cancer [10,11]. Although well described as a MMP inhibi-
tor, other cellular activities associated with Timp1 seem to be indepen-
dent ofMMP inhibition, such as proliferation promotion and apoptosis
inhibition [12], including anoikis resistance [13]. In both cases, studies
have been suggested that MMP-independent effects of TIMP1 on cell
growth and survival may be mediated by their direct binding to a pu-
tative cell surface receptor [14].
Timp1 is expressed by a variety of cell types and tissues, and its expression
is induced by external stimuli such as phorbol esters, serum, cyto-
kines, and growth factors [9]. The mechanisms of Timp1 regulation have
been intensively investigated but still remain largely unknown. Its induction
occurs primarily at the transcription level involving activator protein 1, spec-
ificity protein 1, nuclear factor κB, and cyclic AMP response element tran-
scription factors [12]. DNA methylation is an important mechanism of
gene expression regulation [15], and some studies indicate thatDNAmeth-
ylation could be responsible for the regulation of Timp1 expression [16].
We studied the correlation between malignant transformation and
anoikis resistance by using an experimental model of murine melanocyte
malignant transformation [17], in which the nontumorigenic melano-
cyte lineage melan-a [18] was subjected to sequential cycles of anchor-
age blockade for 96 hours. Progressive morphologic alterations were
observed along each deadhesion cycle, culminating in the establishment
of nontumorigenic melan-a sublines corresponding to intermediate
phases of malignant transformation found after two and four cycles of
anchorage blockade (2C and 4C lineages, respectively). In addition, dis-
tinct tumorigenic lineages, both slow-growing (4C3−) and fast-growing
melanoma lineages (4C3+ and Tm5), were established from spheroids
formed after a new anchorage blockade cycle of 4C cells [17]. Previous
gene expression analysis showed up-regulation of Timp1 gene expres-
sion in Tm5 melanoma cells (unpublished data). Here, we report an
increase in Timp1 expression during melanoma genesis, related to pro-
gressive Timp1 gene demethylation, which is causally associated with the
increase in anoikis resistance but not with the acquisition, by itself, of a
fully transformed malignant phenotype.
Materials and Methods
Mice
Female C57Bl/6, 6 to 8 weeks old, were obtained from and housed
in the animal facilities at the Instituto Nacional de Farmacologia,
Universidade Federal de São Paulo (SP, Brazil). The animals were kept
in a specific pathogen-free facility, under 12-hour daylight cycles, with-
out food restriction, under the International Guiding Principles for
Biomedical Research Involving Animals (CIOMS), Genebra (1985).
All animal procedures were approved by our institutional animal care
and ethics committee.
Cell Lines and Culture
Murine melanocyte lineage melan-a [18] and melan-a cell sub-
lines 2C, 4C, 4C3−, 4C3+, and Tm5, established after submitting
melan-a cells to sequential substrate adhesion impediment cycles [17],
were maintained in RPMI 1640 (Gibco, Carlsbad, CA), pH 6.9, con-
taining 5% fetal bovine serum (Gibco), 40 mg/L gentamicin, and
200 nM phorbol 12-myristate 13-acetate (Sigma, St Louis, MO) at
37°C in 5% CO2.
Substrate Adhesion Blockade Assay
To ensure an anchorage-independent growth condition, 105 cells
were plated on 1% agarose-treated dishes and cultured for different
times at 37°C in 5% CO2. Cells in suspension were collected from
agarose-treated dishes, and cell viability was determined using the stan-
dard methyl thiazol tetrazolium assay (MTT; Amresco, Solon, OH) as
described previously [19].
5-Aza-2′-Deoxycytidine Treatment
Melan-a cells were seeded at a density of 2 × 106 cells in a 10-mm
dish. After 24 hours, cells were incubated with fresh culturemediumwith
or without 5 μM of the demethylating agent 5-Aza-2′-deoxycytidine
(5-Aza-CdR; Calbiochem, Darmstadt, Germany) for 48 hours. Every
day, the medium was changed, and no significant cell death was ob-
served. RNA was isolated from 5-Aza-CdR–treated and nontreated
melan-a cells, and the expression of Timp1 was analyzed by reverse
transcription–polymerase chain reaction (RT-PCR) using the housekeep-
ing gene β-actin as an internal control. PCR products were visualized on
an ethidium bromide–stained 1% agarose gel.
Reverse Transcription–Polymerase Chain Reaction
The cell lines were grown as a monolayer until 70% confluent, and
total RNA was isolated with TRizol (Invitrogen, Carlsbad, CA), ac-
cording to the manufacturer’s instructions. One microgram of RNA
was reverse-transcribed to complementary DNA (cDNA) with Super-
script III (Invitrogen). The resulting single-strand cDNA were am-
plified by PCR in a reaction mixture containing 75 mM Tris-HCl,
pH 9.0, 2 mM MgCl2, 50 mM KCl, 20 mM (NH4)2SO4, 0.4 mM
of each deoxynucleotide triphosphate, 0.4 μM of each primer, 1 U of
BioTools DNA Polymerase–Recombinant from Thermus thermophilus
(BioTools, Madrid, Spain). The thermal cycling conditions were as
follows: initial 5 minutes at 94°C, followed by cycles of denaturing at
94°C for 45 seconds, with combined annealing at 55°C for 45 seconds
and extension at 72°C for 1 minute. To select the optimal PCR condi-
tions, the number of PCR cycles was varied. The β-actin messenger
RNA (mRNA) was used to normalize the amounts of RNA in the cell
samples, and the intensities of the resulting PCR bands were used to
calculate the ratio of Timp1/β-actin intensities for each cycle. Band in-
tensities were quantified using ImageJ 1.38 software (Image Processing
and Analysis in Java, Wayne Rasband, National Institutes of Health,
Bethesda, MD; http://rsb.info.nih.gov/ij/). Each PCR was done in trip-
licate. PCR fragment amplification was confirmed by agarose gel stain-
ing with ethidium bromide. The PCR primers were as follows: Timp1
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forward 5′ GCTAAAAGGATTCAAGGC 3′; Timp1 reverse 5′
GCACAAGCCTAGATTCCG 3′; Actin forward 5′ CGAGGCCCA-
GAGCAAGAGAG 3′; Actin reverse 5′ AGGAAGAGGATGCGG-
CAGTGG 3′.
Western Blot Analysis
Cells of subconfluent cultures were trypsinized, rinsed with PBS, and
lysed directly in cold lysis buffer (50 mM Tris-HCl [pH 8.0], 100 mM
NaCl, 50 mM NaF, 0.5% Nonidet P-40, 1 mM phenylmethylsulfonyl
fluoride, 1 mM sodium orthovanadate, 10 μg/ml aprotinin, and 10 μg/
ml leupeptin) for 15 minutes on ice, followed by centrifugation at
14,000 rpm for 15 minutes at 4°C. The supernatant was collected
and protein concentration was measure by Bio-Rad protein assay dye
reagent concentrate (Bio-Rad, Hercules, CA). Equivalent amounts
of protein (80 μg) were separated on 15% sodium dodecyl sulfate–
polyacrylamide electrophoresis gel and transferred to polyvinylidene
fluoride membranes (Amersham, Piscataway, NJ). Proteins were de-
tected using rabbit polyclonal anti-Timp1 antibody (ABR, Golden,
CA) and the signal was detected using horseradish peroxidase–conjugated
goat anti–rabbit immunoglobulin G antibody (KPL; Gaithersburg,
MD) followed by development using chemiluminescence substrate
(SuperSignal West Pico Chemiluminescent Substrate; Pierce Chemical,
Rockford, IL).
Immunofluorescence Analysis
Cell lines (2 × 104 per well) were plated on glass coverslips, grown as
a monolayer until 70% confluence, washed twice in PBS, fixed in 3.7%
paraformaldehyde in PBS for 15 minutes at −20°C, and washed again
in PBS. Coverslips were blocked with 1% BSA in PBS (1% BSA-PBS)
for 30 minutes at room temperature. Cells were incubated for 1 hour
with rabbit anti-Timp1 polyclonal antibody (ABR) at room tempera-
ture, washed three times with 1% BSA-PBS, and incubated with an
Alexa 488–conjugated antirabbit immunoglobulin G antibody (Mo-
lecular Probes, Carlsbad, CA) for 45 minutes and for 5 minutes with
4′-6-diamidino-2-phenylindole. After five washes with PBS, slides were
mounted with antifade solution and analyzed in a fluorescence micro-
scope (Carl Zeiss, Göttingen, Germany).
Quantification of DNA Methylation by Methylation-Sensitive
Single-Nucleotide Primer Extension
The average methylation at three different CpG sites present in
Timp1 promoter was quantified using methylation-sensitive single-
nucleotide primer extension (Ms-SNuPE) as described previously [20].
Genomic DNA treated with sodium bisulfate as described by Frommer
et al. [21]. Briefly, 6 μg of genomic DNA diluted in 20 μl of deionized
water was denatured for 20 minutes at 95°C, and 5 μl of 3 M NaOH,
pH 5.2, was added to the DNA and the solution was incubated for
20 minutes at 45°C. Denatured DNA was incubated in a total volume
of 250 μl with freshly prepared 3.1 M sodium bisulfite/0.5 mM hydro-
quinone, pH 5.0, for 16 hours at 55°C under mineral oil. The bisulfite-
treated DNA was purified by using a Wizard Mini Preparation Kit
(Promega, Madison, WI), according to the manufacturer’s instructions
and resuspended in 50 μl of deionized water. NaOHwas added to a final
concentration of 0.3 M; DNA was incubated at room temperature for
10 minutes, followed by precipitation in 350 μl of a solution containing
20 mg/ml of glycogen, 0.3 M of NaOAc (pH 5.2), and 85% of ethanol
for 50 minutes at −80°C. Precipitated DNA was resuspended in 40 μl
of deionized water. Two microliters of bisulfite-treated DNAwas ampli-
fied by PCR using the primers as follows: S1, 5′ TGGGTGGATGAG-
TAATG 3′, and Timp1 SNuPE reverse, 5′CTAACTAAAAATCCTAA-
TACCTACAA 3′. The PCR conditions were 94°C for 3 minutes,
44 cycles of 94°C for 1 minute, 52°C for 1 minute, and 72°C for 1 min-
ute. The PCR products were separated by electrophoresis through a
2% agarose gel, purified from the gel using QIAquick Gel Extraction
Kit (Qiagen, Valencia, CA), and eluted in 40 μl of H2O. The single-
nucleotide extensions were obtained adding 4 μl of the template to
6μl of reactionmixture containing 1× PCR buffer, 1 μMSNuPEprimer
(S1, S2 5′ TTATTTTTTATTGTGTAGTTTTTGT 3′ or S3 5′ AT-
TAGAGGTAAGTGGGAGT 3′, one for each reaction), 1 μCi (32P)
dCTP or (32P)dTTP, and 1 U of 1:1 Taq/TaqStart antibody (BD Bio-
sciences Clontech, Palo Alto, CA). This mixture was incubated at 95°C
for 30 seconds, at 51°C for 30 seconds, and finally at 72°C for 1 minute
and then combined with 5 μl of stop solution (95% formamide, 20 mM
EDTA [pH 8.0], 0.05% bromophenol blue, and 0.05% xylene cyanol)
before being denatured at 94°C for 5 minutes and loaded onto a 15%
denaturing polyacrylamide gel (Tris-borate-EDTA buffer, 14.25% acryl-
amide, 0.75% bis-acrylamide, 7 M urea). Methylation levels were quan-
tified on a PhosphorImager Analysis System (Molecular Dynamics,
Sunnyvale, CA). The methylation status of the Timp1 promoter and
first exon represents the average methylation levels of three CpG sites.
Plasmid Construction and Transfection
Stable melan-a and Tm5 cell lines overexpressing Timp1 (ma T1S and
Tm5 T1S, respectively) were generated by RT-PCR amplification of
full-length coding sequence from Tm5 using the gene-specific EcoRI-
flanked (underlined) forward primer 5′ TTGAATTCACCACCAT-
GATGGCCCCCTTTGCA 3′ and XhoI-flanked (underlined) reverse
primer 5′TTCTCGAGTCATCGGGCCCCAAGGGATC3′, digested
with EcoRI and XhoI restriction enzymes and subcloning into the EcoRI/
XhoI cut pcDNA3.1 vector (Invitrogen). The inserts were sequenced
to confirm the desired DNA sequence. Stable transfectants were pro-
duced by transfecting with Lipofectamine 2000 Transfection Reagent
(Invitrogen) and selected during 15 days in medium containing 2 mg/
ml Geneticin (G418; Gibco). Transfection with pcDNA3.1 containing
green fluorescence protein (GFP)–coding sequence (ma GFP and Tm5
GFP) was used as control for transfection efficiency. Transfectants were ex-
panded and analyzed for transgene expression using semiquantitative RT-
PCR,Western blot, and immunofluorescence analysis, as described above.
Flow Cytometry
Cell cycle analysis was performed to quantify sub-G1 population of cells
in suspension. Percentage of cells presenting DNA fragmentation—
sub-G1 population—were determined by the CellQuest software using
a FACSCalibur cytometer (Becton Dickinson, San Juan, CA) as de-
scribed previously [22]. Briefly, different cell lines were maintained in
suspension (105 cells). After 96 hours, cells were washed, fixed with
ice-cold ethanol (70% final concentration), resuspended in 0.5-ml solu-
tion containing 50 μg/ml propidium iodide and 20 μg/ml DNAse-free
RNAse in PBS, and incubated for 30 minutes at 37°C. Ten thousand
events were evaluated per assay.
Colony Formation in Soft Agar
Cells (103 cells per well) were suspended in 3 ml of 0.3% agarose
in complete culture medium. This suspension was layered over 3 ml
of 0.6% agarose medium base layer in 35-mm-diameter dishes. After
21 days, cells were stained with 2 ml of crystal violet solution and
washed extensively with water, and colonies were counted using an
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inverted bright field microscope at a ×2 magnification. This assay was
performed in duplicate.
In Vivo Tumorigenesis Assay
Cells were harvested after trypsin treatment of subconfluent mono-
layers, counted, and then suspended in PBS. Cells (2 × 105) in 0.1 ml
of PBS were injected subcutaneously into the flank of syngeneic
C57Bl/6 female mice. Tumor growth was monitored by daily caliper
measurements. Tumor volumes (mm3) were calculated as follows:
(d 2 × D) / 2. Each experimental group consisted of five animals.
Experimental Metastasis
Cells of subconfluent cultures were trypsinized, suspended in RPMI
with 10% fetal calf serum, spun down, suspended in PBS, counted, and
adjusted to the necessary concentration. Cells (2 × 105) in 0.1ml of PBS
were injected into the lateral tail vein of syngeneic C57Bl/6 mice with a
27-gauge needle. The mice were killed 21 days after injection, lungs
were surgically removed, and metastatic foci in the lungs were macro-
scopically scored. Each experimental group consisted of five animals.
Databases
Oncomine Cancer Microarray database http://www.oncomine.org
[23] was used to study gene expression of Timp1 in human melanoma,
breast cancer, colorectal cancer, lymphoma, and non–small cell lung car-
cinoma. Only gene expression data obtained from a single study using
the same methodology were compared. All data were log-transformed,
median was centered per array, and the standard deviation was normal-
ized to one per array [23]. Statistical comparisons in database were
done with Student’s t-tests and P values were calculated using adjustment
for multiple testing and false discoveries as described at http://www.
oncomine.org [23]. A gene was considered as overexpressed when its
mean value in tumor samples was significantly higher to its mean value
in the normal tissue counterpart (P ≤ .05).
Data Analysis
All experiments were repeated for at least two to three times with simi-
lar results. One-way analysis of variance (ANOVA) with Tukey multiple
comparisons posttest and two-way repeated-measures ANOVA with
Bonferroni posttest were performed using GraphPad Prism version 4.00
forWindows (GraphPad Software, SanDiego, CA; www.graphpad.com).
P values <.05 were considered statistically significant.
Results
Melanocyte Malignant Transformation Associated with
Anoikis Resistance
To study a possible correlation between neoplastic transformation
and anchorage-independent growth, we analyzed the acquisition of
anoikis resistance during murine melanocyte malignant transformation.
Substrate adhesion blockade assay was performed by culturing cells in
suspension for 96 hours in 1% agarose-coated dishes to prevent cell
anchorage, and cell viability was determined by MTT assay. As shown
in Figure 1A, melanoma cell lines became 1.6- to 2.5-fold more re-
sistant to anoikis when compared with melan-a cells. In fact, the non-
tumorigenic 4C cell line also presented augmented anoikis resistance,
similar to 4C3− slow-growing melanoma cells. The acquisition of this
phenotype was also evaluated by culturing cells in soft agar during
21 days (Figure 1B) and revealed a similar result as the one found in
substrate adhesion blockade assay (Figure 1A), showing that melanoma
cells survive 6- to 10.3-fold more than the parental lineage. Together,
these results show progressive increase in cell survival in anchorage-
independent conditions during the first steps of malignant transforma-
tion along tumor progression, even after tumor establishment.
Timp1 Expression Increases during Melanocyte Malignant
Transformation and Neoplastic Progression
Some studies have shown increases in TIMP1 expression related to
a poor prognosis in cancer [24,25]. Using our model, we wished to
examine the expression pattern of Timp1 during melanocyte malig-
nant transformation and neoplastic progression. Because Timp1 expres-
sion is induced by phorbol esters, and melan-a cells require it for
growth, all cells in this study were cultured in the presence of phorbol
12-myristate13-acetate. The expression patterns of Timp1 in the dif-
ferent lineages representing distinct stages of neoplastic development
(nontumorigenic 2C and 4C cell lines, tumorigenic slow-growing 4C3-
melanoma lineage, and tumorigenic fast-growing 4C3+ and Tm5
Figure 1. Melanocyte malignant transformation associated with
anoikis resistance. (A) Cell lines were maintained in suspension for
96 hours, and cell viability was determined by MTT assay. (B) Cell
lines were cultured in soft agar for 21 days, and the number of colo-
nies was counted. ma indicates melan-a cells; 2C and 4C, melan-a
cells submitted to two and four substrate adhesion blockade cycles,
respectively; 4C3−, slow-growing melanoma cell line; 4C3+, Tm5,
fast-growing melanoma cell lines. Bars, SD of the mean of six sam-
ples. *P < .05, **P < .01, ***P < .001. P value was determined by
one-way ANOVA.
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melanoma lineages) were analyzed in comparison to those in parental
melanocyte lineage melan-a. This analysis was performed in all lineages
cultured in adhesion condition (melan-a, 2C, 4C, 4C3−, 4C3+, and
Tm5) (Figure 2A) and also in melan-a cells cultured in suspension for
1, 3, 5, and 24 hours (data not shown). Semiquantitative RT-PCR re-
vealed significant up-regulation of Timp1 expression in all six analyzed
melan-a–derived cell lines cultured in adhesion conditions compared
with that in melan-a cells (Figure 2A). Basal levels of Timp1 expression
was only detected in melan-a cells cultured on plastic, whereas no ex-
pression was detectable by RT-PCR analysis in melan-a cultured in sus-
pension for different times (data not shown). To compare our results with
the findings in human melanoma, Timp1 expression was investigated in
human cancer using the publicly available gene expression data, Onco-
mine Cancer Microarray database (http://www.oncomine.org) [23,26].
We found an augment in Timp1 expression in human melanoma com-
pared with normal skin and benign nevus, their normal counterparts
(Figure 2B). Together, these in silico data and our result suggest that
Timp1 expression may be involved in melanoma genesis and/or progres-
sion (Figure 2A).
Progressive Timp1 Promoter Demethylation Associated to
Timp1 Expression along Neoplastic Progression
Given that previous data from our laboratory showed a significant
alteration in the global DNA methylation level in this model along
neoplastic transformation ([27] and data not shown), and DNA meth-
ylation was demonstrated as being a possible regulatory mechanism
of Timp1 expression [16], we tested whether DNA demethylation in-
duced by 5-Aza-CdR would induce Timp1 expression in melan-a cells.
After treatment, Timp1 expression in melan-a cells was found to be
highly elevated (Figure 3A). For that reason, we wished to confirm
whether DNA methylation has a correlation with Timp1 expression
in this model. Thus, using Ms-SNuPE assay, the average methylation
at CpG dinucleotides within Timp1 promoter (S1) and first exon (S2
and S3; Figure 3B) was analyzed. The DNA methylation level in the
promoter and exonic non–CpG island of Timp1 was quantified in all
lineages, including ma–5-Aza-CdR cells, melan-a cells cultured in sus-
pension for 5 and 24 hours, and nontreated melan-a–derived lineages
cultured in adhesion (Figure 3, C and D). Whereas melan-a melano-
cytes presented the analyzed region methylated, nontumorigenic 4C
cell line and all melanoma cell lines (4C3−, 4C3+, and Tm5) showed
the same region demethylated. Curiously, nontumorigenic 2C cells
showed an intermediate grade of demethylation in these CpG sites
compared with parental cell line (melan-a) and melan-a–derived mela-
nomas (4C3−, 4C3+, and Tm5). The Timp1 gene methylation level
correlates strongly and inversely with its expression (Figure 3D).
Timp1 Overexpression Does Not Induce In Vitro
Cell Proliferation
The progressive increase inTimp1 expression observed duringmelan-a
malignant transformation suggests that its expression might be func-
tionally related to neoplastic development. Considering the relationship
between Timp1 expression and acquisition of anoikis-resistant pheno-
type [12], we tested the functional significance of increased Timp1 ex-
pression during neoplastic progression by transfecting Timp1 (T1S) in
melan-a and Tm5 cells. Timp1 overexpression in transfected clones was
confirmed by RT-PCR and immunofluorescence microscopy (Figure 4,
A and B).
Homeostasis of cell number in tissues depends on the balance be-
tween proliferative and apoptotic indexes. Because Timp1 may regulate
proliferation in some contexts [9,12], we askedwhether increased Timp1
expression observed along malignant transformation was related to an
altered proliferation rate. Accordingly, proliferation index was estimated
by MTT assay in different times and revealed a very similar prolifera-
tion rate in Timp1-overexpressing cells and their controls, both in non-
tumorigenic and tumorigenic lineages (Figure 4C). These data showed
that the augmented Timp1 expression observed during neoplastic pro-
gression (Figure 2) does not affect cell proliferation in this model.
Figure 2. Increased expression of Timp1 throughout melanocyte
malignant transformation. (A) Timp1 expression was analyzed in
melan-a cells and melan-a–derived cell lines by RT-PCR. The graph
represents the Timp1/β-actin mRNA ratio for each sample obtained
by semiquantitative RT-PCR for each cycle (P < .0001). The β-actin
expression was used to normalize the amounts of mRNA in cell
samples, and the intensities of resulting PCR bands were used to
calculate the ratio of Timp1/β-actin intensities. Units on y-axis are
arbitrary. (B) Box plots showing increased expression of TIMP1 in
human melanoma compared with normal skin and benign nevus
[24]. The y-axis represents normalized expression. Shaded boxes
represent the interquartile range (25th-75th percentile). Whiskers
represent the 10th to 90th percentile. The bars denote the median.
Reference refers to microarray reference database. P values for cor-
relation are shown below. ma indicates melan-a cells; 2C and 4C,
melan-a cells submitted to two and four substrate adhesion block-
ade cycles, respectively; 4C3−, slow-growing melanoma cell line;
4C3+, Tm5, fast-growing melanoma cell lines. *P < .05, **P <
.01, ***P < .001. P value was determined by one-way ANOVA.
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Melan-a Melanocytes Overexpressing Timp1
Become Anoikis-Resistant
Apoptosis inhibition by Timp1may result from its ability to stabilize
cell-ECM interactions by inhibiting MMPs. In this context, Timp1
would not protect cells against apoptosis induced by loss of cell-
substrate interactions. Then, melan-a, ma GFP, ma T1S, Tm5, Tm5
GFP, and Tm5 T1S cells were cultured in suspension conditions.
Trypan blue staining showed 100%melan-a cell viability up to 24 hours
in suspension (data not shown). After 96 hours, cell viability was de-
termined by MTT assay, showing that Timp1-overexpressing cells
remained more viable in suspension compared with their controls (Fig-
ure 5A). Ma T1S cells became resistant to anoikis when compared
Figure 3. Timp1 promoter demethylation is associated with Timp1 expression along melanoma genesis. (A) Analysis of Timp1 expression
by RT-PCR after in vitro treatment of melan-a cells with 5 μM 5-Aza-CdR for 2 days. Every day, the medium was changed, and no significant
cell death was observed between the two groups. ma− indicates nontreated melan-a cells (positive control); ma+, melan-a cells treated
with 5-Aza-CdR. (B) Schematic representation of CpG sites location in Timp1 promoter and first exon. S1, S2, and S3 indicate CpG di-
nucleotide analyzed by Ms-SNuPE. Arrow indicates transcriptional start site. (C and D) Quantitative methylation analysis of three CpG sites
in the promoter and first exon of Timp1 gene in various DNA samples using Ms-SNuPE. The percentage of methylation at each CpG site
was determined by the C:T signal ratio (left axis). The average methylation of the three CpG sites is shown at the bottom of each panel.
Methylation levels were quantified on a PhosphorImager Analysis System. In D, the curve in the graph represents Timp1/β-actinmRNA ratio
(right axis). skin indicates DNA extracted frommouse normal skin;ma, melan-a cells;ma–5-Aza-CdR, melan-a cells treated with 5-Aza-CdR;
D5h, D24h, melan-a cells cultured in suspension for 5 and 24 hours, respectively; 2C, 4C, melan-a cells submitted to two and four substrate
adhesion, blockade cycles, respectively; 4C3−, slow-growingmelanoma cell line; 4C3+, Tm5, fast-growingmelanoma cell lines. P< .0001.
P value was determined by one-way ANOVA.
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with their anoikis-sensitive controls (2.2-fold more than ma and
2-fold more than ma GFP). This resistance was also increased in
Timp1-overexpressing melanoma cells (1.2-fold more than Tm5 and
1-fold more than Tm5 GFP), a lineage already resistant to anoikis (Fig-
ure 1). Anoikis-resistant phenotype was also evaluated by culturing cells
in soft agar. As shown in Figure 5B, seven-fold ma T1S cells remained
viable when compared with the control (ma and ma GFP cells), even
after 21 days of being cultured in soft agar. In melanoma, the super
expression of Timp1 was responsible for maintaining more cells viable
in anchorage-independent condition (1.5-fold) when compared with its
controls. Interestingly, maT1S cells were able to survive in soft agar as its
tumorigenic counterpart. Thus, Timp1 expression can prevent anoikis
in melan-a cells.
Timp1 Overexpression Is Related to In Vivo Aggressiveness
Phenotype in Murine and Human Melanoma
Because ma T1S cells were able to grow independent of anchorage in
semisolid agar and this ability became a classic assay for in vitro evalua-
tion of malignant transformation of various cultured cell lines [28], we
examined whether Timp1 overexpression was capable to cause ac-
quisition of a fully transformed malignant phenotype in these cells.
Even after injecting 107 cells subcutaneously in the flank of syngeneic
C57Bl/6 mice, no tumor development was observed in animals trans-
planted with melan-a, ma–5-aza-CdR, ma GFP, or ma T1S cells (data
not shown). When melanoma cells overexpressing Timp1 (2 × 105 cells
per animal) were injected subcutaneously or intravenously in mice
(5 animals per group), the latency time for tumor appearance decreased,
Figure 4. Timp1 overexpression does not induce in vitro cell proliferation both in melan-a melanocytes and Tm5 melanoma cells. Timp1
expressionwas analyzed by RT-PCR (A) and indirect immunofluorescence (B) in melan-a and Tm5 cells transfected with Timp1. The graphics
in A represent the Timp1/β-actin expression ratio for each sample obtained by RT-PCR. The β-actin expression was used to normalize the
amounts of RNA in cell samples, and the intensities of the resulting PCR bands were used to calculate the ratio of Timp1/β-actin intensi-
ties. Units on y-axis are arbitrary. (B) Indirect immunofluorescence using Timp1-specific antibody (ABR). (C) In vitro cell proliferation was
quantified byMTT assay. GFP-transfected cells were used as transfection control.ma indicates melan-a cells; Tm5, fast-growingmelanoma
cell line;GFP, GFP-transfected cells; T1S, Timp1-transfected cells. Bars, SD of themean of five samples. **P< .01, ***P< .001. P value was
determined by one-way ANOVA.
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tumor volume increased (Figure 6A), and metastatic potential had a
substantial augment (Figure 6B).
Because Timp1 overexpression in murine melanoma cells cause
enhancement in tumor malignancy (Figure 6, A and B) and its increase
is related with negative prognosis in many human cancers [10,11], we
used Oncomine Cancer Microarray database [23] to investigate the
expression of TIMP1 in human metastatic melanoma compared with
primary melanoma [29]. Also, we evaluated TIMP1 expression in five
other human malignant tumor types and their primary tumor counter-
parts [30–35]. Increased expression of TIMP1was seen in all metastases
analyzed when compared with primary tumors (Figure 7). It is impor-
tant to note that the finding of increased expression levels of Timp1 in
our direct analysis of tumor samples (Figure 6, A and B), associated with
unfavorable clinical characteristics, is consistent with studies of micro-
array gene expression data in different human tumor types analyzed,
including melanoma (Figure 7).
Taken these data into account, TIMP1might be a new useful marker
for cancer progression because increased levels of its protein has been
found in serum of patients with different aggressive malignancies
[36,37], including melanoma [38]. Given that, we analyzed the level
of Timp1 in supernatant of all cell lines studied in this work. Surpris-
ingly, no detectable level of Timp1 protein was found by Western blot
analysis (data not shown). This result may be explained by the fact that
coimmunoprecipitation of Timp1 with β1-integrin were observed in
all lineages studied here (data not shown), suggesting the involvement
Figure 5. Melan-a melanocytes overexpressing Timp1 become
anoikis-resistant. Timp1-overexpressing melan-a and Tm5 cells were
maintained in suspension for 96 hours. Cell viability (A) was deter-
mined by MTT assay in triplicate. In B, melan-a and Tm5 cells were
cultured in soft agar medium for 21 days, and the number of colo-
nies was counted. ma indicates melan-a cells; Tm5, fast-growing
melanoma cell line; C , nontransfected cells; GFP, GFP-transfected
cells; T1S, Timp1-transfected cells. Bars, SD of themean of analyzed
samples. *P< .05, **P< .01, ***P< .001. P value was determined
by one-way ANOVA.
Figure 6. Timp1 overexpression is related to in vivo aggressive-
ness phenotype inmurine and humanmelanoma. (A) Tumorigenicity
assay in vivo. Mice were subcutaneously injected with 2 × 105 Tm5
cells. Tumor growth was monitored by daily caliper measurements.
(B) Experimental metastasis assay. Tm5 cells (2 × 105) were in-
jected via caudal vein. Mice were killed 23 days later, and their lungs
were removed. Each experimental group consisted of five ani-
mals. Tm5 indicates fast-growing melanoma cell line; Tm5 GFP,
GFP-transfected Tm5 cells; Tm5 T1S, Timp1-transfected Tm5 cells.
Bars, SD of the mean of five animals per group. ***P< .001. P value
was determined by two-way ANOVA.
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of Timp1 protein in intracellular signaling pathway, leading to anoikis-
resistant phenotype.
Discussion
It is well known that both cell-cell and cell-ECM interactions play crucial
roles in determining melanocyte appropriate functions in the epidermis,
in humans, or in the dermis, in mice. Loss of these interactions is ob-
served during melanoma progression, and human melanocytes are
found ectopically in the dermis not only in melanoma lesions but also
in dysplastic nevi, considered a premalignant lesion. The presence of
normal cells in an inappropriate environment prevents their association
with the ECM and then disrupts survival signals resulting in anoikis [3].
This kind of apoptosis is believed to contribute to the maintenance of
proper cell number, geographic architecture, and position in epithelia
organs. Apart from its relevance in physiological conditions, loss of
anchorage dependency is believed to be one of the key mechanisms to
tumor progression and malignant transformation because the cells are
able to proliferate detached and spread from the primary tumor without
undergoing anoikis [39,40]. The distinct ability of tumor cells to grow in
suspension, semisolid media, or multicellular spheroid culture has been
frequently linked to anchorage-independent growth [41] and, more
recently, to anchorage independent survival [42]. Despite the strong
Figure 7. Association of TIMP1 expression with prognosis. Representative data are shown across multiple independently published micro-
array studies as indicated. The y-axis represents normalized expression. Shaded boxes represent the interquartile range (25th-75th per-
centile). Whiskers represent the 10th to 90th percentile. Bars, median. P values for correlation are shown below.
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correlation between the resistance of transformed cells to anoikis and their
ability to form tumors in vivo, direct evidence for a causal relationship
between them remains unknown.
To explain some of these interrelationships in a more direct manner,
we established an in vitromurine carcinogenesis model [17], which spe-
cifically favors the acquisition of anoikis resistance of a nontumorigenic
melanocyte lineage, melan-a [18]. In this model, the sequential expo-
sure of melan-a cells to substrate anchorage impediment cycles leads to
the establishment of cell lines with a markedly reduced susceptibility to
anoikis (Figure 1). Melan-a cells sublines 2C and 4C became progres-
sively more resistant to anoikis, although these lineages were not able to
form tumors in vivo. Melanoma cell lines (4C3−, 4C3+, and Tm5),
obtained by limiting dilution after a new deadhesion cycle of 4C cells,
are also anoikis-resistant (Figure 1) and grow as tumors when injected
subcutaneously in syngeneic mice, with different latency times for
tumor appearance [17]. Previous cDNA microarray analysis revealed
an up-regulation of Timp1 expression in Tm5 melanoma cells when
compared with their parental cell line, melan-a. These results were ini-
tially unexpected considering the well-established function of Timp1 in
the inhibition of MMPs-mediated ECM degradation, tumor cell inva-
sion, and metastasis formation in different tumors [43–46] as well as in
melanoma [47–52].
Besides the number of studies showing antitumor effects of Timp1,
there are also different works reporting TIMP1 protumor effects in
different tumor types [24,53–57], including melanoma [58]. Actually,
TIMP1 is upregulated in many cancer types, and a high level of TIMP1
correlates with a poor prognosis [16,24,36,38,59–62]. In addition,
studies have suggested that TIMP1 may also carry predictive informa-
tion on response to treatment [63,64].
These contradictory events may be due to other important functions
of Timp1. It has been shown that Timp1 induces proliferation and
apoptosis in a wide range of cell types by mechanisms that are appar-
ently independent of MMPs [12]. Previously, Li et al. [13] showed that
TIMP1 expression protects human breast epithelial cells from differ-
ent kinds of apoptosis, including anoikis. In the present study, we have
shown during melanocyte malignant transformation a progressive up-
regulation of Timp1 even in melanocyte lineages corresponding to pre-
malignant lesions (as 2C and 4C cell lines; Figure 2A), in parallel to a
successive increase of anoikis-resistant phenotype (Figure 1). In fact,
increase in TIMP1 expression is also seen during human melanoma
genesis [26], as showed in Figure 2B.
It was shown that cancer genome is globally hypomethylated when
compared with their normal counterparts [65], and changes in DNA
methylation pattern, particularly in the promoter CpG islands, can
also occur [66]. In our model, we observed a significant global hyper-
methylation when melanocytes are maintained in suspension and a
progressive global DNA hypomethylation during tumor progression
([27], and data not shown). These results suggest that there are changes
in the methylation pattern of melan-a cells during the substrate ad-
hesion blockade cycles, which might be important for the expression
of some genes and silencing of others, resulting to a new expression
gene pattern related to the malignant phenotype. Taking these changes
into account and considering the fact that Timp1 expression can be
regulated by DNA methylation [52], Timp1 expression in melan-a cells
was evaluated after treatment with 5-Aza-CdR (Figure 3A). The strong
reexpression of Timp1 led us to use the Ms-SNuPEmethod to examine
the methylation status in CpG sites in Timp1 promoter and in the
first exon of melan-a cells treated and nontreated with 5-Aza-CdR
(Figure 3C ) and melan-a–derived lineages (Figure 3D). We demon-
strated that Timp1, whose promoter and first exon present CpG-rich
regions instead of CpG islands (Figure 3B), has its expression regulated
by DNA methylation because our data show the augment of Timp1
expression in melan-a cells, occurring after 5-Aza-CdR treatment (Fig-
ure 3C). This result might explain a possible inverse correlation between
promoter demethylation and Timp1 expression during melanocyte ma-
lignant transformation (Figure 3D). It is possible that other CpG sites
are demethylated earlier and have more important transcription regula-
tory function than those studied. Whereas most studies report promoter
CpG islands hypermethylation leading to gene silencing [67], some re-
cent studies have shown that DNA methylation can also affect the tran-
scription of genes whose 5′ untranslated region had lowCpGdensity and,
in case of these non–CpG islands genes, the correlation between methyl-
ation and transcription is inverse [68]. Aberrant expression of genes that
do not contain bona fide CpG islands in their promoters, which is ap-
proximately 40% of human genes [69,70]. In addition, these works
have shown correlations between methylation of non–CpG islands and
tissue-specific expression. As the demethylation process seemed to be
stable once initiated, its function would seem to be an enhancement of
the amount of transcription of Timp1 in these cells to facilitate the anoikis
resistance during the malignant transformation process.
To determine whether increased Timp1 expression would be associ-
ated with the increase of anoikis resistance and, consequently, with the
acquisition of a fully transformed malignant phenotype as suggested by
observations associating Timp1 with potentiation of carcinogenesis and
with poor clinical outcome, we took a genetic approach using a trans-
fection assay to overexpress Timp1 in two different lineages, the non-
tumorigenic melan-a melanocytes and the tumorigenic Tm5 melanoma
cells (Figure 4). Results from the current study provide insight into
Timp1 function as an inhibitor of cell death induced by anchorage-
independent growth conditions and highlight the relevance of this
inhibition once tumors have already formed. In melan-a cells, the over-
expression of Timp1 resulted in an anoikis-resistant lineage capable not
only of surviving but also of growing when they were cultured in suspen-
sion, even after 96 hours, and in soft agar medium for 21 days (Figure 5).
This result is supported by observations suggesting that Timp1 could be an
important contributor to epithelial carcinogenesis, especially during early
stages of neoplastic progression [24]. In addition, these authors showed
that Timp1 can inhibit tissue gelatinolytic activity in tumor stroma
without inhibiting tumor progression or development of metastases.
Overexpression of Timp1 in malignant Tm5 melanoma augmented
the anoikis resistance when cultured in suspension and increased the
malignancy of these cells in vivo, suggesting that anoikis inhibition by
Timp1 may be critical for anchorage-independent viability of dissemi-
nating cells during tumor cell metastasis (Figure 6). Taking into account
that Tm5 T1S cells do not present an increase in the proliferation rate
(Figure 4) or in the invasive potential in vitro (data not shown) com-
pared with their control (Tm5 GFP), we believe that Timp1 has a role
in tumor-promoting, ever since these cells showed a higher capability
to survive in the absence of normal matrix components (Figure 5),
resulting in the increase of tumor volume (Figure 6A). This fact also
explains the increase in the number of metastatic foci in lungs when
animals were inoculated with these cells (Figure 6B). This explanation
was supported by Zhu et al. [6], who demonstrated that the selection
in vitro of cells resistant to anoikis increases the metastatic potential of
melanoma cells in a murine experimental model. In fact, many studies
support the importance of anoikis resistance as a crucial phenotype
for metastatic cells because tumor cells that intravasate into the circu-
lation and extravasate into secondary tissue sites are either deprived of
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matrix or exposed to foreign matrix components [71]. Our data provide
evidence that Timp1 expression is required for the acquisition of an
anoikis-resistant phenotype in nontumorigenic melanocyte lineages and
is implicated in a more aggressive phenotype of tumorigenic melanocyte
cell lines. These data and ours are sustained by those reports showing
that patients submitted to clinical trials with synthetic metalloproteinase
inhibitors fail to show any alterations in overall survival or time to pro-
gression compared with placebo group [72,73]. By a meta-analysis ap-
proach, TIMP1 was found significantly overexpressed in metastatic
melanoma compared with nonmetastatic melanoma [29], likewise in
other human invasive tumor types, with TIMP1 overexpression cor-
related with unfavorable clinical characteristics [30–35].
In our studies, melanocyte malignant transformation was obtained
after sequential cycles of substrate adhesion blockade. Increased levels
of Timp1 seem to confer anoikis resistance in all cell lines derived from
melanocytes anchorage blockade (premalignant and malignant cell
lines). Considering that β1-integrins, the main receptor for ECM com-
ponents, have already been described to take part of a cell surface com-
plex with CD63 and TIMP1, activating integrin-mediated cell survival
signaling pathways in human breast epithelial cells [14], it is reasonable
suppose that alterations in cell-matrix interactions might interfere in
Timp1 signaling pathways. Preliminary immunoprecipitation assay sug-
gested Timp1 association with β1-integrin in all lineages studied in
this work. Although themolecular mechanism by which the connection
between Timp1 and β1-integrin induces cell survival in those cells
remains to be defined, we have found that Timp1 is a potent inhibitor
of anoikis, in which Timp1 expression is required for the acquisition of
an anoikis-resistant phenotype in nontumorigenic melanocyte line-
ages, and is implicated in a more aggressive phenotype of tumorigenic
melanocyte cell lines. Accordingly, in our model, the anoikis resistance
is needed to melanoma malignancy but is insufficient for acquisition of
tumorigenic competence by melanocytes cells in vivo.
All of these data support a critical function of TIMP1 and highlight
the complex effects that this molecule can exert along tumorigenesis. As
discussed elsewhere [9,12,74], there are many ways that could explain
the TIMP1 protumor effects, and all of them should be considered
and further investigated in our model.
In conclusion, these findings provide evidence that Timp1 protects
murine melanoma cells from anoikis, and the increase in Timp1 expres-
sion along malignant transformation is associated with progressive gene
demethylation. Consequently, the expression of Timp1 resulted in in-
creased anoikis resistance, indicating that this molecule has protumor
functions in this model, but alone is not capable of inducing a fully
transformed malignant phenotype of nontumorigenic cells. Consid-
ering the elevated expression of Timp1 since the early phases of mela-
noma genesis associated with anoikis resistance, it is reasonable suppose
that Timp1 expression might be a valued marker for melanocyte ma-
lignant transformation.
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